MIST(MIST)
MIST
ANALYST COVERAGE7 analysts
BUY
▲ +426.3%upside to target
L $6.00
Med $8.00consensus
H $8.00Key MetricsTTM
Market Cap$130.55M
Revenue TTM$1.78M
Net Income TTM-$68.36M
Free Cash Flow-$51.23M
Gross Margin94.7%
Operating Margin-3669.4%
Net Margin-3832.0%
Return on Equity-339.4%
Return on Assets-35.3%
Debt / Equity3.81
Current Ratio9.18
EPS TTM$-0.52
PRICE
Prev Close
1.50
Open
1.53
Day Range1.48 – 1.53
1.48
1.53
52W Range1.00 – 3.06
1.00
3.06
25% of range
VOLUME & SIZE
Avg Volume
2.0M
FUNDAMENTALS
P/E Ratio
-2.4x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.68
Low vol
TECHNICAL
RSI (14)
35
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 119 days
Sep 18
MIST News
About
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States.
Philippe DouvilleFounder, Strategic Advisor & Member of Scientific Advisory Board
Philip T. Sager FACC FAHA FHRSChief Medical Advisor & Member of the Scientific Advisory Board
David SandovalGeneral Counsel & Chief Compliance Officer
Jeff MooreVice President of Sales
Jeff NelsonChief Operating Officer
Lorenz MullerChief Commercial Officer
David Bharucha FACCChief Medical Officer
Guy RousseauSVP of Regulatory Affairs and Quality Management
Amit HasijaChief Financial Officer & Executive Vice President of Corporate Development
Joseph G. OlivetoChief Executive Officer, President & Director
Roshan GirglaniVice President of Marketing
Anita HolzVice President & Head of Medical Affairs